(Q44532762)

3 December 2017

title

Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial (English)

1 reference

3 December 2017

main subject

acute coronary syndrome

1 reference

Lampros K Michalis

1

1 reference

3 December 2017

Christos S Katsouras

2

1 reference

3 December 2017

Nikos Papamichael

3

1 reference

3 December 2017

Kostas Adamides

4

1 reference

3 December 2017

Katerina K Naka

5

1 reference

3 December 2017

John Goudevenos

6

1 reference

3 December 2017

Dimitris A Sideris

7

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

3 December 2017

published in

American Heart Journal

1 reference

3 December 2017

volume

146

1 reference

3 December 2017

issue

2

1 reference

3 December 2017

page(s)

304-310

1 reference

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

Low-molecular-weight heparins for acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

Low-molecular-weight heparin : A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

Low-molecular-weight heparins: pharmacologic profile and product differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

New data on the pharmacology of heparin and low molecular weight heparins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900179-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-8703(03)00179-0

1 reference

3 December 2017

1 reference